IB Net Payout Yields Model

Invest like me - only at Covestor.com

Viking Therapeutics: Panic Creates Opportunity

By -

 

  • Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders.
  • The Phase 2 trial demonstrated 12.2% weight loss in 13 weeks, with progressive results and potential for further improvement with longer dosing periods.
  • Concerns over high discontinuation and GI side effects are noted, but these issues are manageable and expected to be addressed in Phase 3 studies.
  • The market's reaction is a major overreaction; I remain ultra bullish on VKTX stock, as the investment thesis is de-risked and the pipeline is well-funded for future growth.
Viking Therapeutics, Inc. (NASDAQ:VKTX) plunged after the market wildly misinterpreted Phase 2 data for a key weight loss drug. The biotech continues to progress to a pivotal Phase 3 study while de-risking the strong pipeline. My investment thesis remains ultra Bullish on the stock, especially after Viking Therapeutics fell over 40% on the oral weight-loss drug data.


Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Stat of the Day: VXO hits 45 again

By -
Not hardly a week removed from hitting 45 on 9/18/08 and the market is back to this extreme level. Usually hitting the 40 level has historically been a huge buy signal for at least the next 4-6 months. Below are the times that 40 has been hit and only 2 times did it exceed 45 in the prior 20+ years until this month. Guess time will tell if this one leads to a huge rally. Date High 10/19/1987 152.48 8/24/1990 40.01 10/27/1997 40.04 8/27/1998 41.46 4/14/2000 41.53 3/22/2001 41.99 9/17/2001 47.7 7/11/2002 41.64 9/18/2008 45.81
Read more

Baidu: Historical Support At $80

By -
Image
Updated - Nov. 15, 2024 Despite leadership in AI and robotaxis in China, Baidu trades right back down to historical support around $80. The stock has now dipped $30 following the volatile move on hope for the Chinese government to fully stimulate the economy.  Update - Aug. 22, 2024 Baidu didn't report anything impressive from robotaxis or AI yet during Q2. The big robotaxi ramp up in Wuhan hasn't started yet. The stock did hold the key $80 support level.  Q2 Non-GAAP EPADS of $2.89 beats by $0.29. Revenue of $4.67B (flat Y/Y) misses by $70M. Adjusted EBITDA was $1.26 billion and adjusted EBITDA margin was 27%.  Adjusted EBITDA for Baidu Core was $1.19 billion and adjusted EBITDA margin for Baidu Core was 32%. Free cash flow was $862 million, and free cash flow excluding iQIYI was $810 million. Original article posted on Aug. 18 Baidu trades at levels first seen in 2011 despite strong growth catalysts. The Chinese search leader will report Q2 earnings on August 22, reveal...
Read more

Nextdoor: Next Step Up

By -
Image
Update - Feb. 28, 2025 Nextdoor reported another strong quarter.  Q4 Revenue of $65.23M (+17.4% Y/Y)  beats by $2.11M . Adjusted EBITDA was $3.0 million, compared to a $14.0 million loss in the year-ago period, reflecting 30 percentage points of year-over-year margin improvement. The social media company guided to weak Q1 results due to going full speed ahead with the NEXT UI updates. This is great news for  investors, but the stock is down some 30% due to the markets short-term focus.  The stock trades at near cash value of $427 million.  Originally posted on Nov. 8 Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Nextdoor has achieved a significant turnaround under the return of founding CEO Nirav Tolia, with 17% revenue growth and record WAUs. The company nearly eliminated losses, reporting a Q3 adjusted EBITDA loss of just $1 million, and expects to be cas...
Read more